HC Wainwright Analysts Give Interpace Diagnostics Group (IDXG) a $3.00 Price Target

HC Wainwright set a $3.00 price target on Interpace Diagnostics Group (NASDAQ:IDXG) in a research report report published on Friday. The firm currently has a buy rating on the business services provider’s stock.

A number of other research firms have also recently commented on IDXG. Zacks Investment Research upgraded shares of Interpace Diagnostics Group from a hold rating to a buy rating and set a $1.25 target price on the stock in a research note on Wednesday, August 22nd. Maxim Group set a $3.00 target price on shares of Interpace Diagnostics Group and gave the stock a buy rating in a research note on Monday, June 11th. LADENBURG THALM/SH SH started coverage on shares of Interpace Diagnostics Group in a research note on Friday, June 22nd. They set a buy rating and a $2.25 target price on the stock. Finally, ValuEngine cut shares of Interpace Diagnostics Group from a hold rating to a sell rating in a research note on Monday, July 2nd. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. The stock presently has an average rating of Buy and a consensus price target of $3.00.

NASDAQ IDXG opened at $1.40 on Friday. Interpace Diagnostics Group has a 12 month low of $0.77 and a 12 month high of $1.80. The company has a market cap of $43.42 million, a price-to-earnings ratio of -1.73 and a beta of 2.35.

Interpace Diagnostics Group (NASDAQ:IDXG) last released its earnings results on Thursday, August 9th. The business services provider reported ($0.07) EPS for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.02. Interpace Diagnostics Group had a negative net margin of 71.14% and a negative return on equity of 34.58%. The company had revenue of $5.50 million for the quarter, compared to analysts’ expectations of $4.80 million. On average, equities analysts forecast that Interpace Diagnostics Group will post -0.33 earnings per share for the current year.

Interpace Diagnostics Group Company Profile

Interpace Diagnostics Group, Inc develops and commercializes molecular diagnostic tests to detect genetic and other molecular alterations associated with gastrointestinal and endocrine cancers. It offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion molecular test that helps physicians better assess risk of pancreaticobiliary cancers using its proprietary PathFinder platform; ThyGenX, an oncogenic mutation panel that helps identify malignant thyroid nodules; and ThyraMIR, an microRNA gene expression assay that helps to classify risk of cancer in thyroid nodules.

Further Reading: Hedge Funds Explained

Receive News & Ratings for Interpace Diagnostics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Interpace Diagnostics Group and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply